当前位置:首页 - 行情中心 - 川宁生物(301301) - 财务分析 - 资产负债表

川宁生物

(301301)

  

流通市值:71.01亿  总市值:256.79亿
流通股本:6.16亿   总股本:22.27亿

资产负债表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
流动资产:
货币资金952,641,981.241,088,331,674.61624,172,142.98929,120,304.76
应收票据及应收账款978,368,112.66939,301,959.141,030,260,734.68937,986,647.37
应收账款978,368,112.66939,301,959.141,030,260,734.68937,986,647.37
应收款项融资960,457,749.57632,971,958.551,152,885,354.441,128,288,662.72
预付款项104,796,966.2889,111,515.36331,334,519.69104,602,965.65
其他应收款合计863,899.5531,437.961,381,331.851,400,724.65
存货1,166,767,035.511,342,070,643.16896,831,183.83920,617,663.5
其他流动资产62,156,479.851,904,684.7650,599,588.1758,140,014.37
流动资产平衡项目0000
流动资产合计4,416,378,924.564,144,223,873.544,088,077,855.644,080,156,983.02
非流动资产:
长期股权投资37,895,227.7415,804,416.1416,218,376.8816,478,172.07
其他权益工具投资24,883,131.3624,883,131.3625,000,00025,000,000
其他非流动金融资产30,000,00030,000,000--
固定资产5,145,153,895.185,274,478,102.295,404,315,012.364,921,711,890.19
在建工程306,932,821.22285,310,350.24190,320,715.8753,825,004.26
使用权资产481,591,643.3485,986,521.14507,499,991.03502,289,845.48
无形资产231,042,455.17235,834,585.17241,004,092.28245,479,966.67
开发支出1,000,0000--
商誉1,365,9741,365,9741,365,9741,365,974
长期待摊费用1,317,379.511,536,942.761,756,506.011,976,069.26
递延所得税资产22,311,722.6120,902,576.9428,264,505.5927,047,851.7
其他非流动资产32,670,082.1833,253,487.5947,553,464.3423,833,323.93
非流动资产平衡项目0000
非流动资产合计6,316,164,332.276,409,356,087.636,463,298,638.296,519,008,097.56
资产平衡项目0000
资产总计10,732,543,256.8310,553,579,961.1710,551,376,493.9310,599,165,080.58
流动负债:
短期借款210,152,563.9210,152,563.9320,177,944.45750,598,611.13
交易性金融负债---256,100
应付票据及应付账款803,122,700.27895,435,078.43688,996,579.63783,994,852.23
其中:应付票据150,000,000150,000,000-0
应付账款653,122,700.27745,435,078.43688,996,579.63783,994,852.23
合同负债27,011,436.3566,818,283.9277,647,641.8618,416,264.19
应付职工薪酬27,320,395.7436,976,800.2226,688,99826,291,277.33
应交税费132,357,282.05103,010,765.84117,137,198.79118,062,164.72
其他应付款合计28,849,180.8412,540,823.6561,922,381.6856,784,192.9
一年内到期的非流动负债740,577,942617,055,432.24699,539,727.29365,957,064.5
其他流动负债2,676,260.945,545,141.464,884,025.961,901,286.74
流动负债平衡项目0000
流动负债合计1,972,067,762.091,947,534,889.661,996,994,497.662,122,261,813.74
非流动负债:
长期借款0146,000,000392,999,999.99650,000,000
租赁负债455,671,460.69451,123,131.01473,060,592.3458,290,832.62
预计负债3,042,782.82-5,468,562.243,215,649.69
递延收益94,564,194.1692,506,096.5793,499,201.3894,562,306.19
递延所得税负债--142,431.4994,557.36
非流动负债平衡项目0000
非流动负债合计553,278,437.67689,629,227.58965,170,787.41,206,163,345.86
负债平衡项目0000
负债合计2,525,346,199.762,637,164,117.242,962,165,285.063,328,425,159.6
所有者权益(或股东权益):
实收资本(或股本)2,227,160,0002,227,160,0002,227,160,0002,227,160,000
资本公积3,286,849,204.193,284,274,587.583,281,363,755.023,278,452,922.5
其他综合收益-99,338.34-99,338.34--
盈余公积325,319,096.72325,319,096.72172,321,265.49172,321,265.49
未分配利润2,349,151,220.872,060,932,688.151,889,524,921.261,579,910,487.94
归属于母公司股东权益平衡项目0000
归属于母公司股东权益合计8,188,380,183.447,897,587,034.117,570,369,941.777,257,844,675.93
少数股东权益18,816,873.6318,828,809.8218,841,267.112,895,245.05
股东权益平衡项目0000
股东权益合计8,207,197,057.077,916,415,843.937,589,211,208.877,270,739,920.98
负债和股东权益合计10,732,543,256.8310,553,579,961.1710,551,376,493.9310,599,165,080.58
公告日期2025-04-292025-04-222024-10-222024-08-27
审计意见(境内)标准无保留意见
TOP↑